drugset / Trial / NCT06081673
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
Phase 2
Active not recruiting
72 enrolled
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NaSingle-groupOpen-labelTreatment
Summary
This study aims to observe and explore the efficacy and safety of Penpulimab combined with chemotherapy for neoadjuvant and adjuvant therapy in patients with resectable head and neck squamous cell carcinoma.
Timeline
- Start
- 2023-10-17
- Primary completion
- 2026-12-30
- Completion
- 2027-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin paclitaxel | Unknown | 260 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |